NEW YORK–(BUSINESS WIRE)–Dave Cantin Group (DCG), one of the world’s largest automotive dealership M&A firms, announced it closed 19 acquisitions, with an average transaction value of $35 million, totaling more than $661 million in the first half of 2022, a 23% increase over the same period last year.
DCG Closes $661 Million in Transactions in First Half 2022
“The automotive dealership business has been incredibly active this year, especially in M&A transactions, driven in part by some of the highest profit margins dealers have ever seen,” said Executive Chairman and CEO Dave Cantin. “Our solid business momentum throughout the first half of 2022 is a testament to the strategic, personalized attention our team brings to every transaction, consistently delivering the best outcome for both buyer and seller.”
DCG successfully closed those 19 transactions in 11 states, with multiple acquisitions occurring in the most active markets of Nevada, Florida, and Texas.
“Manufacturers and analysts expect 2022 to be the most profitable year dealerships have ever recorded, as inventories remain at near-record-low levels,” adds Brian Brown, President of DCG Acquisitions.
DCG has closed billions in acquisitions since its founding in 2018 and is on track to close $1.35 billion in transactions by year’s end, making 2022 another record-breaking year for the company.
About Dave Cantin Group
DCG, founded in 2018 and headquartered in New York City, today is one of the world’s largest and most successful automotive M&A firms. As a holding company, DCG is comprised of subsidiaries designed to support the firm’s mission to build, grow, enhance, and secure clients’ legacies in the automotive industry. DCG Acquisitions is the Mergers & Acquisitions arm specializing in automotive buy/sell transactions. DCG Capital provides capital-focused services for automotive dealers. DCG Media curates automotive-specific intelligence and data and disseminates information through various channels. DCG Giving is a nonprofit that aims to benefit child and adolescent cancer research and treatment nationwide. To learn more, visit www.davecantingroup.com